Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Rigel Pharmaceuticals, Inc. (RIGL) had Revenue of $69.46M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$69.46M
Net Income	$27.90M
Cost of Goods Sold	$4.75M
Gross Profit	$64.71M
Operating Expenses	$41.04M
Operating Income	$28.42M
Non-Operating Income/Expense	$-0.80M
Pre-Tax Income	$27.62M
Normalized Pre-Tax Income	$27.62M
Income after Taxes	$27.90M
Income from Continuous Operations	$27.90M
Consolidated Net Income/Loss	$27.90M
Normalized Income after Taxes	$27.90M
EBIT	$28.42M
EBITDA	$28.56M
Weighted-Average Shares Outstanding (Basic)	18.04M
Weighted-Average Shares Outstanding (Diluted)	19.16M
Earnings per Share (EPS) (Basic)	$1.55
Earnings per Share (EPS) (Diluted)	$1.46
Balance Sheet Financials
Current Assets	$214.93M
Property, Plant, and Equipment	$0.05M
Long-Term Assets	$27.61M
Total Assets	$242.53M
Current Liabilities	$94.40M
Long-Term Debt	$29.97M
Long-Term Liabilities	$30.52M
Total Liabilities	$124.92M
Common Equity	$117.61M
Tangible Shareholders Equity	$92.27M
Shareholders Equity	$117.61M
Common Shares Outstanding	18.14M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$53.67M
Cash Flow from Investing Activities	$-67.00M
Cash Flow from Financial Activities	$5.17M
Beginning Cash	$56.75M
End Cash	$48.59M
Increase/Decrease in Cash	$-8.15M
Stock-Based Compensation	$9.96M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.28
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.20
Debt to Equity Ratio	0.51
Gross Margin	93.16%
Operating Margin	40.91%
EBIT Margin	40.91%
EBITDA Margin	--
Pre-Tax Profit Margin	39.76%
Profit Margin	40.17%
Free Cash Flow	$53.66M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.29
Inventory Turnover	0.36
Receiveable Turnover	1.51
Days Sales in Receivables	59.50
Return on Equity	23.72%
Return on Tangible Equity	30.24%
Return on Assets	11.50%
Return on Investments	18.91%
Book Value Per Share	$6.48
Free Cash Flow per Share	$2.80
Operating Cash Flow per Share	$2.80

Data from Zacks Investment Research, Inc.